Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03114059Completed

5 Years Long Term Results After Standalone CyPass-Implantation

Role: lead

NCT03184428Completed

Posterior Capsule Opacification Following Cataract Surgery With Implantation of the MICS IOL L313

Role: lead

NCT03292614Completed

Measurement of Refractive SE Following Implantation of LS313 MF30 IOL

Role: lead

All 3 trials loaded